PLX3397, a kinase inhibitor specifically tailored for CSF-1R, synergizes with anti-PD-1 therapy to enhance the infiltration and antitumor activities of CD8+ T cells within tumor tissues (Shi et al., 2019). Here, CD8A is linked to neoplasm.